DarioHealth (NASDAQ:DRIO) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of DarioHealth (NASDAQ:DRIO) from a hold rating to a sell rating in a report released on Sunday.

DRIO has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th. Stifel Nicolaus set a $16.00 price target on DarioHealth in a report on Friday, November 14th. Finally, TD Cowen reiterated a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $32.00.

DarioHealth Stock Performance

NASDAQ DRIO opened at $11.64 on Friday. The company’s 50 day simple moving average is $11.99 and its two-hundred day simple moving average is $11.98. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.55 and a quick ratio of 4.02. DarioHealth has a 1 year low of $5.93 and a 1 year high of $17.74. The stock has a market capitalization of $78.69 million, a PE ratio of -1.04 and a beta of 1.05.

Hedge Funds Weigh In On DarioHealth

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd increased its position in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,511 shares of the company’s stock after buying an additional 43,513 shares during the quarter. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.